Shenzhen Edge Medical Co., Ltd. (Edge Medical-B) disclosed that on 24 June 2026 it bought back 479,800 H-shares on the Hong Kong Stock Exchange. The purchase was executed entirely on-market under the company’s existing share-repurchase mandate dated 16 June 2025.

The repurchased shares were acquired at prices ranging from HK$34.70 to HK$38.00 apiece, translating into a volume-weighted average cost of HK$36.53 per share and an aggregate consideration of HK$17.52 million. All repurchased shares have been retained as treasury stock.

Following the transaction, Edge Medical’s outstanding share count (excluding treasury shares) fell by 0.1469% to 326.15 million shares, while the treasury stock balance increased to 1.62 million shares. The total issued share capital remains unchanged at 327.76 million shares until any future cancellation of treasury shares.

Since receiving shareholder authorisation to repurchase up to 32.36 million shares, the company has cumulatively bought back 1.62 million shares, representing 0.50% of the issued shares outstanding on the mandate date. In accordance with Hong Kong listing rules, Edge Medical is subject to a moratorium on issuing new shares or disposing of treasury shares until 24 July 2026.